Valeant said to weigh a Salix buy; Ironwood's GERD drug moves into Phase IIb;

@FierceBiotech: Third Rock starts a $45M Revolution to soup up natural remedies. News | Follow @FierceBiotech

@JohnCFierce: That Merck BTD on HCV--not looking so revolutionary after $GILD and $ABBV trendsetters. Third to market. Release | Follow @JohnCFierce

@DamianFierce: Here's Revolution Medicines cofounder Marty Burke on the concepts behind its synthetic chemistry platform. Video | Follow @DamianFierce

> Valeant Pharmaceuticals ($VRX) is reportedly weighing an offer for the troubled Salix Pharmaceuticals ($SLXP). News

> Ironwood Pharmaceuticals' ($IRWD) gastroesophageal reflux disease drug successfully reduced heartburn in patients with bile reflux in a Phase IIa trial, the company said, clearing the way for Phase IIb. Results

> The New Yorker examines the long, controversial history of psychedelics developed as therapeutic agents. More

Medical Device News

@FierceMedDev: T2 Biosystems scores $8.5M deal with Canon U.S. Life Sciences to develop Lyme disease test. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Google is making human skin to test cancer-detecting device. More | Follow @VarunSaxena2

@EmilyWFierce: Guardant Health ropes in $50M in Series C financing for tumor profiling test. More from FierceDiagnostics | Follow @EmilyWFierce

> NeuroPace reveals positive study results for neurostimulation epilepsy implant. More

> FDA approves Medtronic transcatheter valve to treat congenital heart disease patients. Article

Pharma News

@FiercePharma: Ackman-led hedge fund Pershing Square scores seat on Zoetis board. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: FDA issues warning letter to a second Apotex plant in India. Data manipulation alleged again. More | Follow @EricPFierce

@CarlyHFierce: Valeant is kicking tires at Salix, but a rival Shire bid could quash the idea. More | Follow @CarlyHFierce

> GlaxoSmithKline blazes trail toward ViiV spinoff, with yea or nay expected midyear. More

> Gilead's Sovaldi, Harvoni push its full-year sales to $25B; earnings beat expectations. News

Drug Delivery News

> Cutting off ovarian cancer blood vessels improves chemo delivery. Story

> 3M seeking pharma licensing partner for its microneedle delivery devices. Report

> Drug delivery guru Robert Langer wins £1M prize for his contributions. Item

> Indian researchers use shock waves to deliver insulin, reducing need for injections. More

> FDA approves tamper-resistant reformulation of Zohydro in continuing battle against opioid abuse. Article

Diagnostics News

> BioNano Genomics hooks $68.4M for tech that spots 'inaccessible genome.' News

> Atlas Genetics reels in $20M in Series C round for rapid infectious disease tests. Report

> T2 Biosystems scores $8.5M deal with Canon U.S. Life Sciences to develop Lyme disease test. Story

> Guardant Health ropes in $50M in Series C financing for tumor profiling test. Item

> Quest Diagnostics teams up with CDC for hepatitis research initiative. Article

Pharma Marketing News

> Arena gets South Korea nod to market Belviq with local firm Ildong Pharmaceuticals. Story

> How big are Gilead's hep C drug discounts? Enough to spook investors. More

> Salix and its lead drug Xifaxan have Valeant sniffing around a deal. Item

> Wary Vertex preps payers for its pricey new CF treatment. Article

> Biogen signs on sports talent for a share-your-story MS contest. Report

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.